Valeant以26亿美元收购Medicis，引领美国皮肤科市场

Pharmadeals Review Pub Date : 2012-11-09 DOI:10.3833/PDR.V2012I9.1803

Heather Cartwright

{"title":"Valeant以26亿美元收购Medicis，引领美国皮肤科市场","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1803","DOIUrl":null,"url":null,"abstract":"Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash. The offer price represents a 39% premium to Medicis’ closing price prior to the announcement of the transaction and values Medicis at approximately US$2.6 B. With the acquisition, Valeant will become the leading player in the US dermatology market.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I9.1803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash. The offer price represents a 39% premium to Medicis’ closing price prior to the announcement of the transaction and values Medicis at approximately US$2.6 B. With the acquisition, Valeant will become the leading player in the US dermatology market.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I9.1803\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Valeant制药公司已同意以每股44美元的现金收购美国皮肤科公司美第奇制药公司的所有未发行普通股。本次收购价较交易宣布前美第奇的收盘价溢价39%，对美第奇的估值约为26亿美元。收购完成后，Valeant将成为美国皮肤病学市场的领军企业。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout

Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash. The offer price represents a 39% premium to Medicis’ closing price prior to the announcement of the transaction and values Medicis at approximately US$2.6 B. With the acquisition, Valeant will become the leading player in the US dermatology market.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量